First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers

  1. Felip, E.
  2. Moreno, V.
  3. Morgensztern, D.
  4. Curigliano, G.
  5. Rutkowski, P.
  6. Trigo, J.M.
  7. Calvo, A.
  8. Kowalski, D.
  9. Cortinovis, D.
  10. Plummer, R.
  11. Maio, M.
  12. Ascierto, P.A.
  13. Vladimirov, V.I.
  14. Cervantes, A.
  15. Zudaire, E.
  16. Hazra, A.
  17. T’jollyn, H.
  18. Bandyopadhyay, N.
  19. Greger, J.G.
  20. Attiyeh, E.
  21. Xie, H.
  22. Calvo, E.
Aldizkaria:
Cancer Chemotherapy and Pharmacology

ISSN: 1432-0843,  0344-5704

Argitalpen urtea: 2022

Alea: 89

Zenbakia: 4

Orrialdeak: 499-514

Mota: Artikulua

DOI: 10.1007/S00280-022-04414-6 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus